Abstract
Monoamine oxidase (MAO, E.C. 1.4.3.4) is a flavin-adenine type of enzyme with two isoforms referred to MAO-A and MAO-B that function for oxidation of monoamines. While MAO-A inhibitors are effective as antidepressant and anxiolytic drugs (e.g. chlorgyline, moclobemide, and lazabemide), inhibitors of MAO-B (e.g. Ldeprenyl, pargyline, and rasagiline) are used against neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases. Considering the need for novel MAO inhibitors due to side effects of the current ones, natural products have become attractive targets for researchers. Up till now, many studies revealed strong MAO inhibitory activity of flavonoid, xanthone, alkaloid, and coumarin derivatives from herbal sources, which also become good models for the synthetic MAO inhibitors. For this purpose, the present review focuses on examples of in vitro and in vivo MAO-inhibiting natural compounds of plant origin from a wide variety of chemical classes isolated mainly between 2000 – 2015.
Keywords: Monoamine oxidase, enzyme inhibition, natural compounds, MAO, flavonoid, alkaloid, coumarin.
Current Pharmaceutical Design
Title:Potential of Natural Products of Herbal Origin as Monoamine Oxidase Inhibitors
Volume: 22 Issue: 3
Author(s): Ilkay Erdogan Orhan
Affiliation:
Keywords: Monoamine oxidase, enzyme inhibition, natural compounds, MAO, flavonoid, alkaloid, coumarin.
Abstract: Monoamine oxidase (MAO, E.C. 1.4.3.4) is a flavin-adenine type of enzyme with two isoforms referred to MAO-A and MAO-B that function for oxidation of monoamines. While MAO-A inhibitors are effective as antidepressant and anxiolytic drugs (e.g. chlorgyline, moclobemide, and lazabemide), inhibitors of MAO-B (e.g. Ldeprenyl, pargyline, and rasagiline) are used against neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases. Considering the need for novel MAO inhibitors due to side effects of the current ones, natural products have become attractive targets for researchers. Up till now, many studies revealed strong MAO inhibitory activity of flavonoid, xanthone, alkaloid, and coumarin derivatives from herbal sources, which also become good models for the synthetic MAO inhibitors. For this purpose, the present review focuses on examples of in vitro and in vivo MAO-inhibiting natural compounds of plant origin from a wide variety of chemical classes isolated mainly between 2000 – 2015.
Export Options
About this article
Cite this article as:
Orhan Erdogan Ilkay, Potential of Natural Products of Herbal Origin as Monoamine Oxidase Inhibitors, Current Pharmaceutical Design 2016; 22 (3) . https://dx.doi.org/10.2174/1381612822666151112150612
DOI https://dx.doi.org/10.2174/1381612822666151112150612 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preparation, Characterization and in vivo Evaluation of Raloxifene Hydrochloride Solid Lipid Nanoparticles
Pharmaceutical Nanotechnology Targeting “Undruggable” Proteins: Design of Synthetic Cyclopeptides
Current Medicinal Chemistry New Cathepsin D Inhibitorswith Hydroxyethylamine Isosteres: Preparation and Characterization
Medicinal Chemistry MicroRNA Landscape in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Progress in Research of K<sub>V</sub>1.1 and K<sub>V</sub>1.3 Channels as Therapeutic Targets
Current Topics in Medicinal Chemistry Prenatal Cocaine Disrupts Serotonin Signaling-Dependent Behaviors:Implications for Sex Differences, Early Stress and Prenatal SSRI Exposure
Current Neuropharmacology Botulinum Toxin: Pharmacology and Clinical Developments: A Literature Review
Medicinal Chemistry Brain Molecules and Appetite: The Case of Oleoylethanolamide
Central Nervous System Agents in Medicinal Chemistry Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Current Drug Therapy Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Efficacy and Safety of Targeting Androgen Receptor in Advanced Breast Cancer: A Systematic Review
Current Cancer Therapy Reviews Interplay Between ACE2 and Angiotensin-(1-7) in the Regulation of Blood Pressure
Current Hypertension Reviews Monoamine Oxidases: The Biochemistry of the Proteins As Targets in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design New Anti-Alzheimer Drugs from Biodiversity: The Role of the Natural Acetylcholinesterase Inhibitors
Mini-Reviews in Medicinal Chemistry Monooxime Bispyridinium Reactivators Bearing Xylene Linker Synthesis and In Vitro Evaluation on Model of Organophosphate-Inhibited Acetylcholinesterase
Medicinal Chemistry Influence of Vanin-1 and Catalytic Products in Liver During Normal and Oxidative Stress Conditions
Current Medicinal Chemistry PredCSF: An Integrated Feature-Based Approach for Predicting Conotoxin Superfamily
Protein & Peptide Letters Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke
Current Pharmaceutical Design Enhanced Pro-Apoptotic Effect of Tetrandrine Loaded Nanoparticles Against Osteosarcoma Cells
Current Drug Delivery